

APPENDIX A

93. A combination that comprises an estrogen agonist/antagonist and a growth hormone secretagogue.
94. The combination of claim 93, wherein the growth hormone secretagogue is 2-amino-N-[2-(3a-(R)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo-[4,3-c]pyridin-5-yl)-1-(R)-benzyloxymethyl-2-oxo-ethyl]-isobutyramide or its L-tartaric acid salt.
95. The combination of claim 93, wherein the estrogen agonist/antagonist is raloxifene or a pharmaceutically acceptable salt thereof.
96. The combination of claim 93, wherein the estrogen agonist/antagonist is (-)-Cis-6-phenyl-5-[4-(2-pyrrolodin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or a pharmaceutically acceptable salt thereof.
97. A method for treating a condition which presents with low bone mass comprising administering to a patient in need thereof a therapeutically effective amount of the combination of claim 93.
98. A method for treating a condition which presents with low bone mass comprising administering to a patient in need thereof a therapeutically effective amount of the combination of claim 94.
99. A method for treating a condition which presents with low bone mass comprising administering to a patient in need thereof a therapeutically effective amount of the combination of claim 95.

100. A method for treating a condition which presents with low bone mass comprising administering to a patient in need thereof a therapeutically effective amount of the combination of claim 96.
101. The method of claim 97 wherein the condition is osteoporosis.
102. A pharmaceutical composition comprising an estrogen agonist/antagonist, a growth hormone secretagogue, and a pharmaceutically acceptable carrier.
103. The composition of claim 102, wherein the growth hormone secretagogue is 2-amino-N-[2-(3a-(R)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo-[4,3-c]pyridin-5-yl)-1-(R)-benzyloxymethyl-2-oxo-ethyl]-isobutyramide or its L-tartaric acid salt.
104. The composition of claim 102, wherein the estrogen agonist/antagonist is raloxifene or a pharmaceutically acceptable salt thereof.
105. The composition of claim 102, wherein the estrogen agonist/antagonist is (-)-Cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydronaphthalene-2-ol or a pharmaceutically acceptable salt thereof.
106. A process for making a pharmaceutical composition comprising combining an estrogen agonist/antagonist, a growth hormone secretagogue, and a pharmaceutically acceptable carrier.
107. The process of claim 106, wherein the estrogen agonist/antagonist is raloxifene, (-)-Cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)]-5,6,7,8-tetrahydro-naphthalene-2-ol or a pharmaceutically acceptable salt thereof.

108. The process of claim 106, wherein the growth hormone secretagogue is 2-amino-N-[2-(3a-(R)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo-[4,3-c]pyridin-5-yl)-1-(R)-benzyloxymethyl-2-oxo-ethyl]-isobutyramide or its L-tartaric acid salt.

291057_1.DOC